XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
License and Collaboration Agreements - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 7 Months Ended
Sep. 30, 2021
Aug. 31, 2021
Jul. 31, 2021
May 31, 2021
Apr. 30, 2021
Mar. 31, 2021
Feb. 28, 2021
Jul. 31, 2020
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2020
Dec. 31, 2021
Jul. 30, 2021
Preferred stock, shares issued (in shares)                 0   0     0 16,944,484
Shares repurchased                     5,000,000        
Shares repurchased, Fair value                     $ 40,000,000.0        
Milestone payment         $ 2,500,000   $ 1,000,000.0                
Acquired IPR&D expense     $ 39,900,000               $ 39,900,000   $ 200,000    
Sale of stock, price per share                 $ 8.00   $ 8.00        
Quarterly fee                   $ 0 $ 1,300,000 $ 0      
Delivery fee                     200,000        
Completion fee                     200,000        
Exercise fee                     1,000,000.0        
Accrued Upfront Fee                 $ 200,000   200,000        
Royalty expense                     $ 0        
Maximum [Member]                              
Royalty Based on Net Sales of Licensed Products, Percentage                     0.50%        
Minimum [Member]                              
Royalty Based on Net Sales of Licensed Products, Percentage                     0.30%        
Payments to acquire royalty                     $ 15,000,000.0        
Research and Development [Member]                              
Quarterly fee                 1,300,000   2,600        
Research Development And Regulatory Milestone                              
Potential milestone payment                     18,000,000.0        
Series A Preferred Stock [Member]                              
Preferred stock, shares issued (in shares)               6,237,500              
Shares issued, Fair value                 40,000,000.0   $ 40,000,000.0        
Shares repurchased                     5,000,000        
Shares repurchased, Fair value                     $ 40,000,000.0        
Common Stock [Member]                              
Shares repurchased                     21,250,000        
Shares repurchased, Fair value                     $ 85,000        
Adimab Assignment Agreement [Member]                              
Preferred stock, shares issued (in shares)               5,000,000              
Milestone payment $ 4,000,000.0 $ 4,000,000.0   $ 2,500,000   $ 1,000,000.0                  
Research and development in process                 0 2,500,000 $ 0 3,500,000      
Adimab Assignment Agreement [Member] | Maximum [Member]                              
Potential milestone payment               $ 24,600,000              
Royalty percentage of sublicense consideration                     55.00%        
Adimab Assignment Agreement [Member] | Minimum [Member]                              
Royalty percentage of sublicense consideration                     45.00%        
Adimab Assignment Agreement [Member] | Research and Development [Member]                              
Recognized expense                 $ 200,000 $ 200,000 $ 500,000 $ 400,000      
Adimab Assignment Agreement [Member] | First Product [Member]                              
Potential milestone payment               16,500,000              
Adimab Assignment Agreement [Member] | Second Product [Member]                              
Potential milestone payment               $ 8,100,000              
Adimab Assignment Agreement [Member] | Series A Preferred Stock [Member]                              
Preferred stock, shares issued (in shares)               5,000,000 5,000,000   5,000,000        
Shares issued, Fair value               $ 40,000,000.0              
Adimab Assignment Agreement [Member] | Common Stock [Member]                              
Shares repurchased               21,250,000              
Shares repurchased, Fair value               $ 85,000              
Adimab Collaboration Agreement [Member]                              
Expenses                 $ 600,000   $ 1,000.0        
Delivery fee                     200        
TSRI                              
Research and development in process                 $ 800,000   $ 1,700,000        
Amount Paid As Pre Paid Funding For Research Plan   $ 1,500,000